Platelet aggregation refers to the process in which individual platelets in the blood clump together to form a blood clot. It is a crucial step in hemostasis, which is the body's natural process of stopping bleeding.
When blood vessels are damaged, platelets activate and adhere to the site of injury releasing chemical signals that attract more platelets to the area. Through a series of complex interactions and signalling pathways, platelets aggregate and form a platelet plug, which helps seal the damaged blood vessel preventing further bleeding.
Platelet aggregation is essential for maintaining normal blood clotting and preventing excessive bleeding. However, abnormal platelet aggregation can lead to blood clotting disorders or increased risk of thrombosis (abnormal blood clot formation).
Platelet aggregation testing is a vital part of haemostasis testing, which is used to check for any blood-related problems or needs. It allows for comprehensive assessment of all potential blood disorders and requirements and is often done in tandem with a platelet count. This helps to determine if the platelets are functioning properly, and if there are any issues with the blood clotting process. It can also be used to diagnose certain conditions, such as von Willebrand disease, and to monitor the effectiveness of treatments for blood disorders. There are three types of tests typically used for platelet aggregation testing: light transmission aggregometry (LTA), multiple electrode aggregometry (MEA), and viscoelastometric testing. These tests are used for screening of platelet function for a bleeding disorder and monitoring of anti platelet drugs.
Building on years of accumulated knowledge and expertise in the field of haemostasis, as well as the practical skills of our in-house teams, we have developed reliable and cost-effective solutions that do not sacrifice quality. Our solutions are designed to provide the best possible results while still being affordable and accessible to all. We strive to ensure that our solutions are of the highest quality, so that our customers can trust that they are getting the best possible product for their money. Over the years, we have developed and refined reagents used to test blood cells for LTA, MEA, and viscoelastometric testing. This type of testing is often used as the initial screening for platelet function, and is used to detect any potential bleeding disorders and to monitor the effectiveness of anti-platelet drugs. Hart Biologicals provides high quality platelet aggregation testing. Our state-of-the-art facilities and quality driven systems deliver results every time.
Our R&D team works closely with customers to define their problem, find a resolution, and identify their specific project needs, from reliable, innovative products, reagents or kits tailored to the customer's specifications, to bespoke research-use only prototype products available for testing. All manufacturing takes place at our Hartlepool headquarters. This allows us to have complete control over our products, processes and documentation, ensuring the highest quality standards are met. We welcome opportunities to collaborate in the development of any new concepts in this ever expanding area of diagnostics.
Hart Biologicals provide product validation, international regulatory support and clinical validation activity for full life-cycle support. We are ISO 13485:2016 certified and comply with Title 21 of the FDA CFR Part 820 as well as EU IVDR. Validation documentation is provided for each stage of the journey, ensuring quality and reducing time-to market. This includes platelet count, platelet aggregation test, blood cell, bleeding disorder and platelet function tests.
We’re proud to be able to complete our full haemostasis catalogue with these vitally important reagents. For more information, or to order from our complete portfolio of blood testing reagents, please click on the below link:
